Brind.

Knight Therapeutics launched TAVALISSE for chronic ITP treatment and began expanding its presence through regional agreements in Latin America.

1 report, 1 independent Updated May 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Knight Therapeutics launched TAVALISSE for chronic ITP treatment and began expanding its presence through regional agreements in Latin America.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped